Cargando…
Outpatient Microdose Induction with Transdermal Buprenorphine: A Case Series
Transdermal buprenorphine is FDA approved for chronic severe pain but has an increasing amount of data supporting its use to transition patients from full opioid agonists to sublingual buprenorphine via a microdose strategy. The literature has primarily focused on patients with a pain diagnosis or w...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9317019/ https://www.ncbi.nlm.nih.gov/pubmed/35885833 http://dx.doi.org/10.3390/healthcare10071307 |